Abstract
Sleeping Beauty transposons have the potential for use as chromosome-integrating vectors for non-viral gene therapy. Recent preclinical data from mouse models for human genetic disorders have shown efficacy for the Sleeping Beauty transposon system in the treatment of hemophilia, tyrosinemia type I, junctional epidermolysis bullosa and type 1 diabetes. Methods have also been developed to deliver Sleeping Beauty transposons to the lung, liver and tumors for treatments for cystic fibrosis, cardiovascular and metabolic diseases, and cancer. Recent studies characterizing site selection for integration and insertional mutagenesis indicate that the Sleeping Beauty transposon system may be a safer alternative than viral approaches for gene therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 513-519 |
| Number of pages | 7 |
| Journal | Current Opinion in Pharmacology |
| Volume | 5 |
| Issue number | 5 SPEC.ISS. |
| DOIs | |
| State | Published - Oct 2005 |
Bibliographical note
Funding Information:We thank Dr. Maura A McGrail for her thoughtful comments. The authors were supported by NIH grants P01 HD32652-07 (PBH and RSM) and R43 HL076908-01.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Awakening gene therapy with Sleeping Beauty transposons'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS